Builder.ai Strengthens Leadership with Craig Saunders from Amazon as New Vice President of Artificial Intelligence
11.6.2024 14:00:00 EEST | Business Wire | Press release
Builder.ai, the AI-powered composable software platform that allows every business and entrepreneur to become digitally powered, is excited to announce the appointment of Craig Saunders as Vice President of Artificial Intelligence. Craig Saunders, a powerhouse in the AI industry, joins Builder.ai from Amazon, where he spent seven transformative years within the Artificial General Intelligence (AGI) organisation.
During his tenure at Amazon, Craig made a significant impact by pioneering technologies for Alexa. He led research and engineering teams building foundational Knowledge Graphs for General Q&A on Alexa, established partnerships with leading universities, and his teams launched challenges within the academic community such as FEVER (Fact Extraction and Verification) to move the state of the art forward on factual accuracy of knowledge graphs. His leadership extended to Natural Language Understanding, including use of seq2seq models in Alexa, and formed the team that federated across multiple Alexa Q&A systems. In 2022, Craig led teams that were building the next generation of textual Large Language Models for Amazon, and advanced personalisation for Alexa.
“Craig’s remarkable achievements in AI - and his visionary approach to multi disciplinary, multi modal AI will enable us to propel Natasha and our AI capabilities to newer frontiers and allow us to drive an even richer customer experience,” said Sachin Dev Duggal, Founder & Chief Wizard, Builder.ai. “His expertise is not just in technology, but in fostering scaled innovation that resonates with customers on a global scale. I’m thrilled to have Craig join the team and excited to see what he and the team add to the Platform and Natasha’s capabilities.”
In his new role, Saunders will lead the AI teams at Builder.ai, focusing on scaling and expanding the company's existing AI capabilities, including Natasha, the world’s first AI product manager, and its new Code Generation System, which automates the transition from a user conversation directly to working code. His expertise will be instrumental in propelling Builder.ai to deliver even more for their customers through tailored software solutions with unprecedented efficiency.
“Joining Builder.ai feels like a natural progression in my career, allowing me to further push the boundaries of AI and machine learning solutions,” adds Craig Saunders. “I’m excited to be a part of the development of cutting-edge AI solutions that will not only transform the way software is created but also empower our customers to achieve their ambitious business goals.”
Craig received a PhD in Machine Learning from the University of London in 2000 and continued in the education sector, working nine years as an academic faculty at Royal Holloway, University of London and the University of Southampton. Utilising his expertise and knowledge, he transitioned to a career at Xerox where he delivered machine learning solutions across diverse industries including transportation, healthcare, and finance. Additionally, Craig has successfully published over 70 academic papers in leading conferences and journals, and holds several patents.
Established in 2016, Builder.ai leads the industry with its AI-powered composable software platform, allowing anyone with an idea to develop an app (web or mobile) more quickly and affordably. By decomposing software into reusable Lego-like features and combining them with cutting-edge AI and a patented software assembly line, Builder.ai has demonstrated global success in enabling customers of all sizes to adopt a software-first approach.
About Builder.ai
Builder.ai® is an AI-powered composable software platform for every idea and company globally. The AI-powered assembly line integrates Lego-like reusable features with Building Blocks™ automation to minimise human effort, leverages a verified network of experts to significantly extend development capabilities, and produces apps with a nearly zero failure rate at a fraction of the cost and time of traditional software development.
Led by serial entrepreneur Sachin Dev Duggal, Builder.ai is reshaping the construction and operation of software with a suite of products and services, including BUILDER STUDIO, BUILDER CLOUD, BUILDER NOW, and STUDIO STORE. Builder.ai was featured on the 2023 Fast Company list of Most Innovative Companies, received the “Hottest AI Startup” and 2022’s “Hottest Scale-Up” awards at the Europas for Europe's successful tech startups, and won the Best COVID-19 Innovation for Recovery at CogX. It was also named 'Visionary' in the 2021 Gartner® Magic Quadrant™ for Multi-experience Development Platforms. Builder.ai is headquartered in London, with employees and hubs in Delhi NCR, Singapore, Los Angeles, Salt Lake City, Sophia Antipolis, and Dubai. For more information, visit Builder.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611122778/en/
Contacts
Stephanie.lowenthal@builder.ai
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom